Our role is to carefully screen each patient and help them choose the solution that best matches their lifestyle.”— Dr.

Viatris Inc. (NASDAQ:VTRS) and Opus Genetics, Inc. (NASDAQ:IRD) revealed topline results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for ...

A new eye drop, Vizz, was recently FDA approved and is helping people regain near vision without glasses. Originally used for glaucoma, the drops are now repurposed for presbyopia (age-related ...

Presbyopia is defined as age-related loss of near vision that affects nearly everyone over age 45. The FDA has approved Vizz, an aceclidine ophthalmic solution 1.44%, making it the first and only ...

The FDA has approved a first-of-its-kind eye drop that addresses a common vision condition. The once-daily drops will treat an age-related condition that causes blurry near vision. The drops are ...

On Thursday, the U.S. Food and Drug Administration approved LENZ Therapeutics, Inc.’s (NASDAQ:LENZ) VIZZ (aceclidine ophthalmic solution, previously known as LNZ100) 1.44%, the first and only ...

SAN DIEGO -- A low-dose formulation of pilocarpine significantly improved visual acuity in presbyopia without adversely affecting distance vision, results of two randomized trials showed. As compared ...